You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTemsirolimus
Accession NumberDB06287
TypeSmall Molecule
GroupsApproved
DescriptionTemsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.
Structure
Thumb
Synonyms
42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin
Torisel
External Identifiers
  • CCI-779
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gd-temsirolimussolution25 mgintravenousGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
ToriselkitWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2007-07-01Not applicableUs
Toriselliquid25 mgintravenousPfizer Canada Inc2008-01-11Not applicableCanada
ToriselConcentrate and diluent for solution for infusion30 mgIntravenous use 1Pfizer Limited2007-11-19Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII624KN6GM2T
CAS number162635-04-3
WeightAverage: 1030.2871
Monoisotopic: 1029.602485741
Chemical FormulaC56H87NO16
InChI KeyCBPNZQVSJQDFBE-FUXHJELOSA-N
InChI
InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1
IUPAC Name
(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
SMILES
OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[[email protected]](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[[email protected]](C)C[[email protected]](C)\C=C\C=C\C=C(C)\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[[email protected]]3C(=O)O2)C[[email protected]]1OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as macrolide lactams. These are cyclic polyketides containing both a cyclic amide and a cyclic ester group.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassMacrolide lactams
Sub ClassNot Available
Direct ParentMacrolide lactams
Alternative Parents
Substituents
  • Macrolide lactam
  • Macrolide
  • Alpha-amino acid ester
  • Beta-hydroxy acid
  • Piperidine
  • Oxane
  • Hydroxy acid
  • Dicarboxylic acid or derivatives
  • Tertiary carboxylic acid amide
  • Cyclic ketone
  • Tertiary amine
  • Secondary alcohol
  • Lactone
  • Lactam
  • Ketone
  • Hemiacetal
  • Carboxylic acid ester
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
PharmacodynamicsNot Available
Mechanism of actionTemsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor.
Related Articles
AbsorptionInfused intravenous over 30 - 60 minutes. Cmax is typically observed at the end of infusion
Volume of distribution

172 L in whole blood of cancer patients; both temsirolimus and sirolimus are extensive distributed partitioned into formed blood elements

Protein binding87% bound to plasma proteins in vitro at a concentration of 100 ng/ml
Metabolism

Primarily metabolized by cytochrome P450 3A4 in the human liver. Sirolimus, an equally potent metabolite, is the primary metabolite in humans following IV infusion. Other metabolic pathways observed in in vitro temsirolimus metabolism studies include hydroxylation, reduction and demethylation.

SubstrateEnzymesProduct
Temsirolimus
Not Available
SirolimusDetails
Route of eliminationExcreted predominantly in feces (76%), 4.6% of drug and metabolites recovered in urine. 17% of drug was not recovered by either route following a 14-day sample collection.
Half lifeTemsirolimus exhibits a bi-exponential decline in whole blood concentrations and the mean half-lives of temsirolimus and sirolimus were 17.3 hr and 54.6 hr, respectively.
Clearance

16.2 L/h (22%)

ToxicityTemsirolimus has been administered to patients with cancer in phase 1 and 2 trials with repeated intravenous doses as high as 220 mg/m2. The risk of several serious adverse events, including thrombosis, bowel perforation, interstitial lung disease (ILD), seizure, and psychosis, is increased with doses of temsirolimus greater than 25 mg.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8908
Blood Brain Barrier-0.9494
Caco-2 permeable-0.664
P-glycoprotein substrateSubstrate0.8122
P-glycoprotein inhibitor IInhibitor0.8098
P-glycoprotein inhibitor IIInhibitor0.7467
Renal organic cation transporterNon-inhibitor0.7636
CYP450 2C9 substrateNon-substrate0.8699
CYP450 2D6 substrateNon-substrate0.8845
CYP450 3A4 substrateSubstrate0.7533
CYP450 1A2 substrateNon-inhibitor0.9126
CYP450 2C9 inhibitorNon-inhibitor0.8957
CYP450 2D6 inhibitorNon-inhibitor0.942
CYP450 2C19 inhibitorNon-inhibitor0.9155
CYP450 3A4 inhibitorNon-inhibitor0.9558
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9398
Ames testNon AMES toxic0.6087
CarcinogenicityNon-carcinogens0.9367
BiodegradationNot ready biodegradable0.9522
Rat acute toxicity2.8760 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9703
hERG inhibition (predictor II)Non-inhibitor0.7479
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Solutionintravenous25 mg
Concentrate and diluent for solution for infusionIntravenous use 130 mg
Kit
Liquidintravenous25 mg
Prices
Unit descriptionCostUnit
Torisel 25 mg kit1467.89USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2187024 No2004-08-102015-04-14Canada
CA2429020 No2009-05-262021-11-13Canada
US5362718 Yes1999-08-152019-08-15Us
US8026276 Yes2006-07-202026-07-20Us
US8299116 Yes2004-01-252024-01-25Us
US8455539 Yes2004-01-252024-01-25Us
US8722700 Yes2004-01-252024-01-25Us
US8791097 Yes2012-11-102032-11-10Us
USRE44768 Yes1999-08-152019-08-15Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00235 mg/mLALOGPS
logP4.39ALOGPS
logP7.13ChemAxon
logS-5.6ALOGPS
pKa (Strongest Acidic)9.96ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area241.96 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity277.07 m3·mol-1ChemAxon
Polarizability112.71 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Kwang-Chung Lee, Ting-Huei Lee, Yen-Shih Tung, Chia-Chen Kao, Tzu-Ai Lee, “Process for preparation of temsirolimus.” U.S. Patent US20100249415, issued September 30, 2010.

US20100249415
General References
  1. Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L: Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol. 2007 Nov;47(11):1430-9. Epub 2007 Oct 3. [PubMed:17913896 ]
External Links
ATC CodesL01XE09
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (402 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Temsirolimus.
3,4-DichloroisocoumarinThe risk or severity of adverse effects can be increased when 3,4-Dichloroisocoumarin is combined with Temsirolimus.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe risk or severity of adverse effects can be increased when 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE is combined with Temsirolimus.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Temsirolimus.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Temsirolimus.
AcetaminophenThe serum concentration of Temsirolimus can be increased when it is combined with Acetaminophen.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Temsirolimus.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Temsirolimus.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Temsirolimus.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Temsirolimus.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Temsirolimus.
AlbendazoleThe serum concentration of Temsirolimus can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Temsirolimus can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Temsirolimus.
AlectinibThe serum concentration of Temsirolimus can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Temsirolimus can be increased when it is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Temsirolimus.
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Temsirolimus.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Temsirolimus.
Alpha-1-proteinase inhibitorThe risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Temsirolimus.
AmantadineThe serum concentration of Temsirolimus can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Temsirolimus.
Aminohippuric acidThe serum concentration of Temsirolimus can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Temsirolimus can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Temsirolimus can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Temsirolimus can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Temsirolimus can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Temsirolimus can be increased when it is combined with Amsacrine.
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Temsirolimus.
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Temsirolimus.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Temsirolimus.
AprepitantThe serum concentration of Temsirolimus can be increased when it is combined with Aprepitant.
AprotininThe risk or severity of adverse effects can be increased when Aprotinin is combined with Temsirolimus.
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Temsirolimus.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Temsirolimus.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Temsirolimus.
AstemizoleThe serum concentration of Temsirolimus can be increased when it is combined with Astemizole.
AsunaprevirThe risk or severity of adverse effects can be increased when Asunaprevir is combined with Temsirolimus.
AtazanavirThe serum concentration of Temsirolimus can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Temsirolimus can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Temsirolimus can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Temsirolimus can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Temsirolimus.
AzelastineThe serum concentration of Temsirolimus can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Temsirolimus can be increased when it is combined with Azithromycin.
BatimastatThe risk or severity of adverse effects can be increased when Batimastat is combined with Temsirolimus.
BenazeprilThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Benazepril.
BenzamidineThe risk or severity of adverse effects can be increased when Benzamidine is combined with Temsirolimus.
BenzocaineThe serum concentration of Temsirolimus can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Temsirolimus can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Temsirolimus.
BevacizumabBevacizumab may increase the cardiotoxic activities of Temsirolimus.
BexaroteneThe serum concentration of Temsirolimus can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Temsirolimus can be increased when it is combined with Biperiden.
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Temsirolimus.
BoceprevirThe risk or severity of adverse effects can be increased when Boceprevir is combined with Temsirolimus.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Temsirolimus.
BortezomibThe metabolism of Temsirolimus can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Temsirolimus can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Temsirolimus.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Temsirolimus.
BromocriptineThe serum concentration of Temsirolimus can be increased when it is combined with Bromocriptine.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Temsirolimus.
BuprenorphineThe serum concentration of Temsirolimus can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Temsirolimus can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Temsirolimus can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Temsirolimus can be increased when it is combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Temsirolimus.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Temsirolimus.
CanagliflozinThe serum concentration of Temsirolimus can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Temsirolimus can be increased when it is combined with Candesartan.
CandoxatrilThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Candoxatril.
CaptoprilThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Captopril.
CaptoprilThe serum concentration of Temsirolimus can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Temsirolimus can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Temsirolimus.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Temsirolimus.
CarvedilolThe serum concentration of Temsirolimus can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Temsirolimus can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Temsirolimus.
CeritinibThe serum concentration of Temsirolimus can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Temsirolimus.
ChloroquineThe serum concentration of Temsirolimus can be increased when it is combined with Chloroquine.
ChlorpromazineThe serum concentration of Temsirolimus can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Temsirolimus.
ChlorpropamideThe serum concentration of Temsirolimus can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Temsirolimus can be increased when it is combined with Chlorprothixene.
CholesterolThe serum concentration of Temsirolimus can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Temsirolimus can be decreased when it is combined with Cholic Acid.
ChymostatinThe risk or severity of adverse effects can be increased when Chymostatin is combined with Temsirolimus.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Temsirolimus.
CilastatinThe risk or severity of adverse effects can be increased when Cilastatin is combined with Temsirolimus.
CilazaprilThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Cilazapril.
CilazaprilThe serum concentration of Temsirolimus can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Temsirolimus can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Temsirolimus.
CiprofloxacinThe serum concentration of Temsirolimus can be increased when it is combined with Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Temsirolimus.
CitalopramThe serum concentration of Temsirolimus can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Temsirolimus can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Temsirolimus can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Temsirolimus.
ClofazimineThe serum concentration of Temsirolimus can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Temsirolimus.
ClomipramineThe serum concentration of Temsirolimus can be increased when it is combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Temsirolimus.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Temsirolimus.
ClotrimazoleThe metabolism of Temsirolimus can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Clozapine.
CobicistatThe serum concentration of Temsirolimus can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Temsirolimus.
ColchicineThe serum concentration of Temsirolimus can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Temsirolimus can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Temsirolimus can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Temsirolimus.
CrizotinibThe metabolism of Temsirolimus can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Temsirolimus.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Temsirolimus.
CyclosporineThe metabolism of Temsirolimus can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Temsirolimus.
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Temsirolimus.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Temsirolimus.
DabrafenibThe serum concentration of Temsirolimus can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Temsirolimus.
DaclatasvirThe serum concentration of Temsirolimus can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Temsirolimus can be increased when it is combined with Dactinomycin.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Temsirolimus.
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Temsirolimus.
DasatinibThe serum concentration of Temsirolimus can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Temsirolimus can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Temsirolimus.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Temsirolimus.
DeferasiroxThe serum concentration of Temsirolimus can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Temsirolimus can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Temsirolimus.
DesipramineThe serum concentration of Temsirolimus can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Temsirolimus.
DesloratadineThe serum concentration of Temsirolimus can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Temsirolimus can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Temsirolimus.
DextromethorphanThe serum concentration of Temsirolimus can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Temsirolimus.
DiclofenacThe serum concentration of Temsirolimus can be increased when it is combined with Diclofenac.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Temsirolimus.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Temsirolimus.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Temsirolimus.
DigoxinDigoxin may decrease the cardiotoxic activities of Temsirolimus.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Temsirolimus.
DihydroergotamineThe metabolism of Temsirolimus can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Temsirolimus.
DiltiazemThe metabolism of Temsirolimus can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Temsirolimus.
DipyridamoleThe serum concentration of Temsirolimus can be increased when it is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Temsirolimus.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temsirolimus.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Temsirolimus.
DoxazosinThe serum concentration of Temsirolimus can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Temsirolimus can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Temsirolimus can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Temsirolimus.
DoxycyclineThe metabolism of Temsirolimus can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Temsirolimus can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Temsirolimus can be decreased when combined with Dronedarone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Temsirolimus.
EcabetThe risk or severity of adverse effects can be increased when Ecabet is combined with Temsirolimus.
EdoxabanThe risk or severity of adverse effects can be increased when Edoxaban is combined with Temsirolimus.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Temsirolimus.
EfavirenzThe serum concentration of Temsirolimus can be decreased when it is combined with Efavirenz.
ElafinThe risk or severity of adverse effects can be increased when Elafin is combined with Temsirolimus.
ElbasvirThe serum concentration of Temsirolimus can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Temsirolimus.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Temsirolimus.
EnalaprilThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Enalapril.
EnalaprilThe serum concentration of Temsirolimus can be increased when it is combined with Enalapril.
EnalaprilatThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Enalaprilat.
EnalkirenThe risk or severity of adverse effects can be increased when Enalkiren is combined with Temsirolimus.
EnzalutamideThe serum concentration of Temsirolimus can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Temsirolimus.
ErgonovineThe serum concentration of Temsirolimus can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Temsirolimus can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Temsirolimus.
ErythromycinThe metabolism of Temsirolimus can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Temsirolimus.
Eslicarbazepine acetateThe serum concentration of Temsirolimus can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Temsirolimus.
EstramustineThe serum concentration of Temsirolimus can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Temsirolimus can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Temsirolimus.
EstroneThe serum concentration of Temsirolimus can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Temsirolimus.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Temsirolimus.
EtoposideThe serum concentration of Temsirolimus can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Temsirolimus can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Temsirolimus.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Temsirolimus.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Temsirolimus.
FelodipineThe serum concentration of Temsirolimus can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Temsirolimus can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Temsirolimus.
FexofenadineThe serum concentration of Temsirolimus can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Temsirolimus.
FingolimodTemsirolimus may increase the immunosuppressive activities of Fingolimod.
FluconazoleThe metabolism of Temsirolimus can be decreased when combined with Fluconazole.
FluoxetineThe serum concentration of Temsirolimus can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Temsirolimus can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Temsirolimus can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Temsirolimus can be increased when it is combined with Flurazepam.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Temsirolimus.
FluvoxamineThe metabolism of Temsirolimus can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Temsirolimus can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Temsirolimus can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Fosinopril.
FosphenytoinThe serum concentration of Temsirolimus can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Temsirolimus can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Temsirolimus can be increased when it is combined with Gefitinib.
GeldanamycinThe risk or severity of adverse effects can be increased when Geldanamycin is combined with Temsirolimus.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Temsirolimus.
GenisteinThe serum concentration of Temsirolimus can be increased when it is combined with Genistein.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Temsirolimus.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Temsirolimus.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Temsirolimus.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Temsirolimus.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Temsirolimus.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Temsirolimus.
GlyburideThe serum concentration of Temsirolimus can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Temsirolimus can be increased when it is combined with Glycerol.
GM6001The risk or severity of adverse effects can be increased when GM6001 is combined with Temsirolimus.
Gramicidin DThe serum concentration of Temsirolimus can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Temsirolimus.
GrepafloxacinThe serum concentration of Temsirolimus can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Temsirolimus can be increased when it is combined with Haloperidol.
HirulogThe risk or severity of adverse effects can be increased when Hirulog is combined with Temsirolimus.
HydrocortisoneThe serum concentration of Temsirolimus can be increased when it is combined with Hydrocortisone.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Temsirolimus.
IdelalisibThe serum concentration of Temsirolimus can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Temsirolimus can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Temsirolimus.
ImipramineThe serum concentration of Temsirolimus can be increased when it is combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Temsirolimus.
IndinavirThe serum concentration of Temsirolimus can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Temsirolimus.
IndomethacinThe serum concentration of Temsirolimus can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Temsirolimus.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Temsirolimus.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Temsirolimus.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Temsirolimus.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Temsirolimus.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Temsirolimus.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Temsirolimus.
IsavuconazoniumThe metabolism of Temsirolimus can be decreased when combined with Isavuconazonium.
IsoflurophateThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Temsirolimus.
IsradipineThe metabolism of Temsirolimus can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Temsirolimus can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Temsirolimus can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Temsirolimus can be increased when it is combined with Ivermectin.
IxazomibThe risk or severity of adverse effects can be increased when Ixazomib is combined with Temsirolimus.
KetamineThe serum concentration of Temsirolimus can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Temsirolimus.
KetoconazoleThe serum concentration of Temsirolimus can be increased when it is combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Temsirolimus.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Temsirolimus.
LansoprazoleThe serum concentration of Temsirolimus can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Temsirolimus can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Temsirolimus.
LeflunomideThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Temsirolimus.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Temsirolimus.
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Temsirolimus.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Temsirolimus.
LevofloxacinThe serum concentration of Temsirolimus can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Temsirolimus.
LevothyroxineThe serum concentration of Temsirolimus can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Temsirolimus can be increased when it is combined with Lidocaine.
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Temsirolimus.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Temsirolimus.
LiothyronineThe serum concentration of Temsirolimus can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Temsirolimus can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Temsirolimus.
LisinoprilThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Lisinopril.
LisinoprilThe serum concentration of Temsirolimus can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Temsirolimus can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Temsirolimus can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Temsirolimus can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Temsirolimus can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Temsirolimus can be increased when it is combined with Losartan.
LovastatinThe metabolism of Temsirolimus can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Temsirolimus can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Temsirolimus can be decreased when it is combined with Lumacaftor.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Temsirolimus.
MaprotilineThe serum concentration of Temsirolimus can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Temsirolimus can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Temsirolimus can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Temsirolimus can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Temsirolimus can be increased when it is combined with Meprobamate.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Temsirolimus.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Temsirolimus.
MethadoneThe serum concentration of Temsirolimus can be increased when it is combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Temsirolimus.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Temsirolimus.
MetoprololThe serum concentration of Temsirolimus can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Temsirolimus can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Temsirolimus can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Temsirolimus can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Temsirolimus.
MifepristoneThe metabolism of Temsirolimus can be decreased when combined with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Temsirolimus.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Temsirolimus.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Temsirolimus.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Temsirolimus.
MitomycinThe serum concentration of Temsirolimus can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Temsirolimus can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Temsirolimus can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Temsirolimus.
ModafinilThe serum concentration of Temsirolimus can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Moexipril.
MorphineThe serum concentration of Temsirolimus can be increased when it is combined with Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Temsirolimus.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe risk or severity of adverse effects can be increased when N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline is combined with Temsirolimus.
NadololThe serum concentration of Nadolol can be increased when it is combined with Temsirolimus.
NafcillinThe serum concentration of Temsirolimus can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Temsirolimus.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Temsirolimus.
NaltrexoneThe serum concentration of Temsirolimus can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Temsirolimus can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Natalizumab.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Temsirolimus.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Temsirolimus.
NefazodoneThe serum concentration of Temsirolimus can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Temsirolimus can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Temsirolimus.
NeostigmineThe serum concentration of Temsirolimus can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Temsirolimus can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Temsirolimus can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Temsirolimus can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Temsirolimus can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Temsirolimus.
NilotinibThe metabolism of Temsirolimus can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Temsirolimus.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Temsirolimus.
NisoldipineThe serum concentration of Temsirolimus can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Temsirolimus can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Temsirolimus can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Temsirolimus.
NorethisteroneThe serum concentration of Temsirolimus can be decreased when it is combined with Norethisterone.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Temsirolimus.
OlaparibThe metabolism of Temsirolimus can be decreased when combined with Olaparib.
OmapatrilatThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Temsirolimus.
OmeprazoleThe serum concentration of Temsirolimus can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Temsirolimus can be increased when it is combined with Osimertinib.
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Temsirolimus.
OuabainOuabain may decrease the cardiotoxic activities of Temsirolimus.
P-NitrophenolThe serum concentration of Temsirolimus can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Temsirolimus can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Temsirolimus can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Temsirolimus can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Temsirolimus.
PantoprazoleThe serum concentration of Temsirolimus can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Temsirolimus can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Temsirolimus.
PentobarbitalThe metabolism of Temsirolimus can be increased when combined with Pentobarbital.
PerindoprilThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Perindopril.
PerindoprilThe serum concentration of Temsirolimus can be increased when it is combined with Perindopril.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Temsirolimus.
PhenobarbitalThe serum concentration of Temsirolimus can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Temsirolimus.
PhenytoinThe serum concentration of Temsirolimus can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Temsirolimus.
PhosphoramidonThe risk or severity of adverse effects can be increased when Phosphoramidon is combined with Temsirolimus.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temsirolimus.
PimozideThe serum concentration of Temsirolimus can be increased when it is combined with Pimozide.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Temsirolimus.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Temsirolimus.
Platelet Activating FactorThe serum concentration of Temsirolimus can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Temsirolimus.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Temsirolimus.
PosaconazoleThe serum concentration of Temsirolimus can be increased when it is combined with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Temsirolimus.
PravastatinThe serum concentration of Temsirolimus can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Temsirolimus can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Temsirolimus.
PrednisoneThe serum concentration of Temsirolimus can be increased when it is combined with Prednisone.
PrimidoneThe metabolism of Temsirolimus can be increased when combined with Primidone.
PrinomastatThe risk or severity of adverse effects can be increased when Prinomastat is combined with Temsirolimus.
ProbenecidThe serum concentration of Temsirolimus can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Temsirolimus can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Temsirolimus.
PromethazineThe serum concentration of Temsirolimus can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Temsirolimus can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Temsirolimus can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Temsirolimus can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Temsirolimus.
QuercetinThe serum concentration of Temsirolimus can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Temsirolimus.
QuinacrineThe serum concentration of Temsirolimus can be increased when it is combined with Quinacrine.
QuinaprilThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Quinapril.
QuinidineThe serum concentration of Temsirolimus can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Temsirolimus can be increased when it is combined with Quinine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Rabies vaccine.
RamiprilThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Ramipril.
RanitidineThe serum concentration of Temsirolimus can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Temsirolimus.
ReboxetineThe serum concentration of Temsirolimus can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Temsirolimus can be increased when it is combined with Regorafenib.
RemikirenThe risk or severity of adverse effects can be increased when Remikiren is combined with Temsirolimus.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Temsirolimus.
RescinnamineThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Rescinnamine.
ReserpineThe serum concentration of Temsirolimus can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Temsirolimus.
RifabutinThe metabolism of Temsirolimus can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Temsirolimus can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Temsirolimus.
RifapentineThe metabolism of Temsirolimus can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Temsirolimus.
RilpivirineThe serum concentration of Temsirolimus can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Temsirolimus.
RitonavirThe serum concentration of Temsirolimus can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Temsirolimus.
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Temsirolimus.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Temsirolimus.
RoflumilastRoflumilast may increase the immunosuppressive activities of Temsirolimus.
RolapitantThe serum concentration of Temsirolimus can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Temsirolimus.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Temsirolimus.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Temsirolimus.
SaquinavirThe serum concentration of Temsirolimus can be decreased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Temsirolimus.
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Temsirolimus.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Temsirolimus.
ScopolamineThe serum concentration of Temsirolimus can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Temsirolimus can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Temsirolimus.
SertralineThe serum concentration of Temsirolimus can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Temsirolimus can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Temsirolimus.
SiltuximabThe serum concentration of Temsirolimus can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Temsirolimus can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Temsirolimus can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Temsirolimus.
SirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Sirolimus.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Temsirolimus.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Temsirolimus.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Temsirolimus.
SorafenibThe serum concentration of Temsirolimus can be increased when it is combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Temsirolimus.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Temsirolimus.
SpiraprilThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Spirapril.
SpironolactoneThe serum concentration of Temsirolimus can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Temsirolimus can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Temsirolimus can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Temsirolimus can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Temsirolimus can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Temsirolimus can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Temsirolimus can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Temsirolimus.
SumatriptanThe serum concentration of Temsirolimus can be increased when it is combined with Sumatriptan.
SunitinibThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Sunitinib.
SunitinibThe serum concentration of Temsirolimus can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Temsirolimus can be increased when it is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Temsirolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Temsirolimus.
TamoxifenThe serum concentration of Temsirolimus can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Temsirolimus.
Taurocholic AcidThe serum concentration of Temsirolimus can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Temsirolimus.
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Temsirolimus.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Temsirolimus.
TelithromycinThe metabolism of Temsirolimus can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Temsirolimus can be increased when it is combined with Telmisartan.
TemocaprilThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Temocapril.
TerazosinThe serum concentration of Temsirolimus can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Temsirolimus can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Temsirolimus can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Temsirolimus can be increased when it is combined with Testosterone.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Temsirolimus.
ThiorphanThe risk or severity of adverse effects can be increased when Thiorphan is combined with Temsirolimus.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Temsirolimus.
TiclopidineThe metabolism of Temsirolimus can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Temsirolimus.
TipranavirThe risk or severity of adverse effects can be increased when Tipranavir is combined with Temsirolimus.
TocilizumabThe serum concentration of Temsirolimus can be decreased when it is combined with Tocilizumab.
TofacitinibTemsirolimus may increase the immunosuppressive activities of Tofacitinib.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Temsirolimus.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Temsirolimus.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Temsirolimus.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Temsirolimus.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Temsirolimus.
TrandolaprilThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Trandolapril.
TrastuzumabTrastuzumab may increase the neutropenic activities of Temsirolimus.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Temsirolimus.
TrazodoneThe serum concentration of Temsirolimus can be decreased when it is combined with Trazodone.
TrifluoperazineThe serum concentration of Temsirolimus can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Temsirolimus can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Temsirolimus can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Temsirolimus can be increased when it is combined with Trimipramine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Temsirolimus.
TroleandomycinThe serum concentration of Temsirolimus can be increased when it is combined with Troleandomycin.
UbenimexThe risk or severity of adverse effects can be increased when Ubenimex is combined with Temsirolimus.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Temsirolimus.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Temsirolimus.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Temsirolimus.
VenlafaxineThe metabolism of Temsirolimus can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Temsirolimus.
VerapamilThe metabolism of Temsirolimus can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Temsirolimus.
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Temsirolimus.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Temsirolimus.
VinblastineThe serum concentration of Temsirolimus can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Temsirolimus.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Temsirolimus.
VincristineThe serum concentration of Temsirolimus can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Temsirolimus can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Temsirolimus.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Temsirolimus.
VoriconazoleThe metabolism of Temsirolimus can be decreased when combined with Voriconazole.
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Temsirolimus.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Temsirolimus.
ZimelidineThe serum concentration of Temsirolimus can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Temsirolimus can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Tfiiic-class transcription factor binding
Specific Function:
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activ...
Gene Name:
MTOR
Uniprot ID:
P42345
Molecular Weight:
288889.05 Da
References
  1. Patard JJ, Pouessel D, Bensalah K, Culine S: Targeted therapy in renal cell carcinoma. World J Urol. 2008 Apr;26(2):135-40. doi: 10.1007/s00345-008-0237-4. Epub 2008 Feb 12. [PubMed:18265991 ]
  2. Radulovic S, Bjelogrlic SK: Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON. 2007 Sep;12 Suppl 1:S151-62. [PubMed:17935273 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:22 / Updated on September 30, 2016 03:38